Manchester Myositis Research Group

Our overall objectives are to improve the way we treat people with myositis by carrying out cutting edge research across all unmet needs. Our multi-disciplinary group aims to answer a range of key research questions, including:
- "What causes myositis?"
- "How can we best treat myositis?"
- "What is the best way to screen for cancer in people with myositis?"
- "How does myositis impact everyday life?"
- "What is the link between myositis and comorbidities?"

Our group utilises a range of methods to answer these key questions, including:
1 - Pathophysiology
2 - Genetics
3 - Clinical trials
4 - Cancer screening
5 - Qualitative work
6 - Epidemiology
7 - Guideline development

Our group has published extensively on myositis epidemiology, genetics and genomics, serology, imaging, cancer screening, and clinical trials.

We have led national and international evidence based guidelines, including the 2022 British Society of Rheumatology Myositis Management Guideline and the 2023 Myositis Cancer Screening Guideline.

We supervise multiple PhD students and regularly supervise external clinical fellows.

We have strong links to hospitals within the Greater Manchester healthcare system, especially Salford Royal Hospital.

Patient and public involvement and engagement (PPIE) is central to our research. We coordinate the MyoVoice Group - the first myositis PPIE group of its kind in the UK. We also closely collaborate with Myositis UK, the national myositis charity.

The Manchester Myositis Research Group is the lead centre for UKMYONET, a community of myositis researchers in the UK, and the EuroMyositis Registry, the largest international myositis registry.